Which companies are Getein Biotech's closest peers?

The cockpit's peer set: Kura Oncology (KURA), Design Therapeutics (DSGN), Geron (GERN), Wave Life Sciences (WVE), Boji Medical Technology (300404.SZ), Apnimed (APMD), Candel Therapeutics (CADL), 4D Molecular Therapeutics (FDMT).

How has Getein Biotech stock performed?

Over six months to 6 Nov 2026 the shares returned -11.8% against -18.8% for the median peer; over one year +3.8%.

← CockpitCompetitor Analysis › 603387.SS Getein Biotech, Inc. Class AOpen in the cockpit ↗

Getein Biotech, Inc. Class A603387.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Momentum neutral 55

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$647M

US dollars, full cap

Free float

57%

of shares outstanding

$/day

$11.3M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

+8.1 pp

WACC 5.2%

Hurdle

-7 pp

Req g minus delivered

Close · CNYCN¥8.51

1D-2.4%

1W+0.7%

1M-16.2%

3M-4.4%

6M-11.8%

YTD+1.7%

1Y+3.8%

ATR %3.9%

52w lowhigh25.5% off high

What Getein Biotech does

Employees: 1,733

Getein Biotech at a glance

Size Getein Biotech (603387.SS) is a China Health Care company (Biotechnology) with a market value of $647M, the 3245th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥8.51 on 6 Nov 2026.

Performance Over six months the shares fell 11.8%, against -18.8% for the median peer and -16.4% for the China market (cap-weighted) — 9th highest of 19 in its peer set.

Growth Revenue grew 7.9% over the last twelve months (peer median +23.1%); the operating margin is 21.3% (peer median -139.9%).

Valuation It trades at 2.7× enterprise value to sales against a peer median of 4.7× (4th cheapest of 14).

Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -7 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 8.1 points above its cost of capital (5.2% WACC).

Relative performance

Six months, rebased to 100: Getein Biotech against the median of its 20 peers (local-currency closes).

Getein Biotech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥1.11B	CN¥1.04B	CN¥1.15B	CN¥1.36B	CN¥1.80B
Revenue growth	—	-9%	-15%	-25%	—
Gross profit	CN¥801M	CN¥659M	CN¥724M	CN¥841M	CN¥1.12B
EBITDA	n/a	CN¥293M	CN¥286M	CN¥303M	CN¥556M
Net income	CN¥293M	CN¥221M	CN¥224M	CN¥280M	CN¥499M
Free cash flow	CN¥355M	CN¥263M	CN¥295M	CN¥84.3M	CN¥305M
Capital expenditure	CN¥121M	CN¥151M	CN¥156M	CN¥258M	CN¥217M
Total debt	CN¥277M	CN¥482M	CN¥582M	CN¥667M	CN¥591M

Quarterly statements and history in the cockpit →

Getein Biotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Getein Biotech is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Getein Biotech is the large dot.

Capital: growth delivered against growth the price implies

Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Getein Biotech is the large dot.

Getein Biotech competitors and peer comparison

How Getein Biotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Getein Biotech against its 20 peers (data as of 6 Nov 2026)
Measure	603387.SS	Peer median	Rank in peer set
1-month return	-16.2%	-9.7%	7th lowest of 21
6-month return	-11.8%	-18.8%	9th highest of 19
Distance from 52-week high	-25.5%	-44.7%	2nd highest of 21
Revenue growth (TTM)	+7.9%	+23.1%	6th lowest of 13
Operating margin	21.3%	-139.9%	highest of 14
EV / Sales	2.7×	4.7×	4th cheapest of 14
Growth the price implies (Req g, 7 yrs)	-8.3%	n/a	—
Growth delivered (Del g)	-1.3%	n/a	—
Hurdle (Req g minus delivered)	-7.0 pp	n/a	—
ROIC minus cost of capital	+8.1 pp	-51.7 pp	highest of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Getein Biotech 603387.SS	China	$647M	-12%	+8%	21%	2.7×	-8.3%	-1.3%
Kura Oncology KURA	United States	$647M	-23%	-7%	-412%	2.0×	n/a	n/a
Design Therapeutics DSGN	United States	$639M	-28%	n/a	n/a	n/a	n/a	n/a
Geron GERN	United States	$636M	-29%	+19%	-8%	1.6×	n/a	n/a
Wave Life Sciences WVE	United States	$664M	-53%	-35%	-321%	3.9×	n/a	n/a
Boji Medical Technology 300404.SZ	China	$664M	+7%	+32%	4%	4.1×	35.4%	+27.2%
Apnimed APMD	United States	$629M	n/a	+380%	-140%	20.3×	n/a	n/a
Candel Therapeutics CADL	United States	$670M	+5%	n/a	n/a	n/a	n/a	n/a
4D Molecular Therapeutics FDMT	United States	$677M	+21%	+278,712%	-214%	3.9×	n/a	n/a
Aura Biosciences AURA	United States	$680M	-22%	n/a	n/a	n/a	n/a	n/a
Shenzhen Weiguang Biological Products 002880.SZ	China	$682M	-22%	0%	18%	4.7×	n/a	n/a
Ascletis Pharma 1672.HK	Hong Kong	$610M	-73%	-59%	-71,976%	2,088.7×	n/a	n/a
Anhui Huaheng Biotechnology 688639.SS	China	$688M	-40%	+7%	3%	2.1×	n/a	n/a
Attovia Therapeutics ATTO	United States	$697M	+744%	n/a	-4,975%	625.6×	n/a	n/a
Genfit GNFT.PA	France	$593M	+19%	+28%	-130%	11.2×	40.0%	+143.5%
Solid Biosciences SLDB	United States	$707M	-9%	n/a	n/a	n/a	n/a	n/a
Climb Bio CLYM	United States	$591M	-10%	n/a	n/a	n/a	n/a	n/a
Sana Biotechnology SANA	United States	$709M	-32%	n/a	n/a	n/a	n/a	n/a
Shouyao Holdings Beijing 688197.SS	China	$726M	-16%	+4,564%	-92%	43.1×	n/a	n/a
Alebund Pharmaceuticals (Jiangsu) 9637.HK	Hong Kong	$576M	n/a	+674%	-495%	25.7×	n/a	n/a
Faeth Therapeutics FTH	United States	$570M	-6%	n/a	n/a	n/a	n/a	n/a

Questions

Which companies are Getein Biotech's closest peers?: The cockpit's peer set: Kura Oncology (KURA), Design Therapeutics (DSGN), Geron (GERN), Wave Life Sciences (WVE), Boji Medical Technology (300404.SZ), Apnimed (APMD), Candel Therapeutics (CADL), 4D Molecular Therapeutics (FDMT).
Is Getein Biotech expensive compared with its peers?: On ev / sales it trades at 2.7× against a peer median of 4.7×, 4th cheapest of 14 in its peer set. For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -7 pp: the price already allows for a slowdown.
How has Getein Biotech stock performed?: Over six months to 6 Nov 2026 the shares returned -11.8% against -18.8% for the median peer; over one year +3.8%.